Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Abstract Background PD-1/PD-L1 play a crucial role as immune checkpoint inhibitors in various types of cancer. Although our previous study revealed that NPM1 was a novel transcriptional regulator of PD-L1 and stimulated the transcription of PD-L1, the underlying regulatory mechanism remains incomple...

Full description

Bibliographic Details
Main Authors: Ge Qin, Fan Bai, Huabin Hu, Jianwei Zhang, Weixiang Zhan, Zehua Wu, Jianxia Li, Yang Fu, Yanhong Deng
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Molecular Medicine
Subjects:
NPM1
NAT10
PD-L1
Immunotherapy
Remodelin
Online Access:https://doi.org/10.1186/s10020-024-00780-4

Internet

https://doi.org/10.1186/s10020-024-00780-4

Similar Items